May 18, 2026 | Press Releases
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to...
May 13, 2026 | Press Releases
– Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future...
Apr 23, 2026 | Press Releases
CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek...
Apr 15, 2026 | Press Releases
CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek...
Mar 30, 2026 | Press Releases
– Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – – Current data package highlights well-tolerated long-term safety profile,...
